Home » Stocks » IMRN

Immuron Limited (IMRN)

Stock Price: $6.87 USD -0.04 (-0.58%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.79 -0.08 (-1.16%) Jan 15, 5:52 PM
Market Cap 38.18M
Revenue (ttm) 1.74M
Net Income (ttm) -2.02M
Shares Out 163.22M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.87
Previous Close $6.91
Change ($) -0.04
Change (%) -0.58%
Day's Open 6.77
Day's Range 6.73 - 6.98
Day's Volume 24,201
52-Week Range 1.60 - 20.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunot...

GlobeNewsWire - 1 month ago

Key Points

GlobeNewsWire - 1 month ago

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoth...

GlobeNewsWire - 2 months ago

Key Points

GlobeNewsWire - 3 months ago

Key Points

GlobeNewsWire - 5 months ago

MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercia...

Benzinga - 5 months ago

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option.

Market Watch - 5 months ago

Shares of Immuron Ltd. IMRN, +56.58% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a re...

24/7 Wall Street - 5 months ago

Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory sy...

GlobeNewsWire - 5 months ago

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immun...

GlobeNewsWire - 5 months ago

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immun...

GlobeNewsWire - 5 months ago

Key Points

GlobeNewsWire - 6 months ago

Key Points

24/7 Wall Street - 7 months ago

The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out.

Market Watch - 7 months ago

The U.S.-listed shares of of Immuron Ltd. IMRN, 1,152.32% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday

Benzinga - 7 months ago

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) are on a roll Tuesday on the back of financing deal for one of its pipeline assets.

GlobeNewsWire - 7 months ago

Key Points

GlobeNewsWire - 8 months ago

MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immu...

GlobeNewsWire - 8 months ago

Key Highlights:

GlobeNewsWire - 9 months ago

MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 o...

GlobeNewsWire - 10 months ago

Key Highlights:

GlobeNewsWire - 11 months ago

Key Highlights:

GlobeNewsWire - 11 months ago

Key Highlights:

GlobeNewsWire - 1 year ago

Key Points

GlobeNewsWire - 1 year ago

MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immun...

GlobeNewsWire - 1 year ago

Key Highlights:

Benzinga - 1 year ago

Shares of thinly traded nano-cap biotech IMMURON LTD/S ADR (NASDAQ: IMRN) were off to a flying start Wednesday morning.

GlobeNewsWire - 1 year ago

Key Highlights:

GlobeNewsWire - 1 year ago

Key Highlights:

Benzinga - 1 year ago

Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose sharply Wednesday on roughly 250 times average volume.

About IMRN

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alc... [Read more...]

Industry
Biotechnology
Founded
1994
CEO
Dr. Jerry Kanellos Ph.D.
Stock Exchange
NASDAQ
Ticker Symbol
IMRN
Full Company Profile

Financial Performance

In 2020, Immuron's revenue was 2.52 million, an increase of 5.49% compared to the previous year's 2.39 million. Losses were -2.93 million, -37.14% less than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Immuron is 6.41, which is a decrease of -6.70% from the latest price.

Price Target
$6.41
(-6.70% downside)